Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia

Lancet Haematol. 2022 Dec;9(12):e864-e865. doi: 10.1016/S2352-3026(22)00294-0. Epub 2022 Oct 22.

Authors

Andrés Gómez-De León¹, Juan Manuel Mejía-Aranguré²

Affiliations

¹ Facultad de Medicina y Hospital Universitario Dr José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
² Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico; Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. Electronic address: jmejia@inmegen.gob.mx.

PMID: 36279878
DOI: 10.1016/S2352-3026(22)00294-0

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Bispecific* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide / therapeutic use
Dexamethasone / therapeutic use
Doxorubicin / therapeutic use
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Vincristine / therapeutic use

Substances

blinatumomab
Antibodies, Bispecific
Dexamethasone
Doxorubicin
Vincristine
Cyclophosphamide